Novo Nordisk (NVO.US) fell 3.3% to $38.48
Show original
In terms of news, Novo Nordisk has received a warning letter from the U.S. Food and Drug Administration (FDA) for failing to report all suspected side effects experienced by patients taking the weight-loss drug Ozempic. The FDA pointed out in the letter that the cases included two deaths and one suicide, all involving patients who had received semaglutide treatment, which is the generic name for Ozempic and Wegovy. The FDA did not specify whether these deaths or other side effects were related to the drug. (Gelonghui)
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Trending news
MoreSmartstop Self Storage REIT Inc has officially reached a land acquisition agreement and plans to develop a brand new Class A self-storage project in Edmonton, Alberta, Canada.
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Origin Materials Inc. announced on March 4 that its board of directors has officially approved a 1-for-30 reverse stock split plan.
Crypto prices
More
Bitcoin
BTC
$69,782.45
+1.21%
Ethereum
ETH
$2,029.14
+0.10%
Tether USDt
USDT
$1
-0.01%
BNB
BNB
$641.22
+0.22%
XRP
XRP
$1.38
+0.51%
USDC
USDC
$1
-0.01%
Solana
SOL
$85.54
-0.52%
TRON
TRX
$0.2854
-0.19%
Dogecoin
DOGE
$0.09426
+3.02%
Cardano
ADA
$0.2614
+1.15%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now